• Approximately 17.2 Million Total Shares Shorted Since August 2009
• Short Squeeze Imminent as Stock nears $0.26 SqueezeTrigger Price

NEW YORK, NY / ACCESSWIRE / May 23, 2016 / Tree Top Industries, Inc. (OTC: TTII) announced today that BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Tree Top Industries (OTC: TTII) after releasing the latest short sale data through May 20, 2016. The total aggregate number of shares shorted since August 2009 is approximately 17.2 million shares. Approximately 40.06% of total trading volume is short selling. The SqueezeTrigger price for all TTII shares shorted is $0.26. A short squeeze is about to begin as shares of TTII are right at their $0.26 SqueezeTrigger Price.

Click here to view Report: http://www.buyins.com/reports/ttii5-22-16.pdf

Click here for SqueezeTrigger: http://www.buyins.com/images2/ttiistr5-22-16.jpg

Click here for Friction Factor: http://www.buyins.com/images2/ttiiff5-22-16.jpg

Click here for detailed explanation: http://www.buyins.com/brochure.pdf

Friction Factor calculates if a fair market is being made in the shares of TTII. 42% of the previous 38 trading days have been positive or bullish-biased and 58% have been negative or bearish-biased.

Regulation SHO requires bona-fide market-making activities to include making purchases and sales in roughly comparable amounts. The Commission has stated that bona-fide market-making DOES NOT include activity that is related to speculative selling strategies for investment purposes of the broker-dealer and is disproportionate to the usual market making patterns or practices of the broker-dealer in that security. Likewise, where a market-maker posts continually at or near the best offer, but does not also post at or near the best bid, the market-maker’s activities would not generally qualify as bona-fide market-making. Moreover, a market-maker that continually executes short sales away from its posted quotes would generally not be considered to be engaging in bona-fide market-making.

BUYINS.NET monitors TTII market-makers daily for compliance with Fair Market-Making Requirements.

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies and comparable valuations.

About Tree Top Industries

Tree Top Industries, Inc. is a publicly traded holding company, with subsidiaries and affiliates that hold intellectual properties, proprietary systems, and trade secrets in the bioscience, clean tech, and global health technologies, as well as interests in the Oil & Gas businesses. The Markowitz Law Firm, led by Warren R. Markowitz, Esq is a boutique law firm based in Las Vegas NV. Founded in 2008, the firm provides litigation and representation to developing and emerging companies and operators. As a litigator and former Wall Street Compliance Officer, Mr. Markowitz, brings a unique mix to the table to protect and advance his client’s needs and interests through relationships with like-minded attorneys in jurisdictions throughout the U.S.

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “will”, or “plans” to be uncertain and forward looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the company’s reports and registration statements filed with the Securities and Exchange Commission.

DISCLAIMER:

BUYINS.NET is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. A third party has paid two thousand five hundred dollars for one month of data provided in this report. TTII has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact:

Mike King
Princeton Research Inc.
702 650 3000

BUYINS.NET

Thomas Ronk
800-715-9999
tom@buyins.net
http://www.buyins.net

SOURCE: Tree Top Industries, Inc.

ReleaseID: 440306

LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include Cloud Peak Energy, Harsco, Uranium Energy, and Fairmount Santrol.

Today, ActiveWallSt.com is promoting its technical alert briefings. Get all of our alerts free by signing up to http://www.activewallst.com/.

Follow these Industrial Metals and Minerals equities recent technical performances on the stock markets below.

Cloud Peak Energy Inc. (NYSE: CLD)

Coal producer Cloud Peak Energy Inc.’s stock finished 2.67% higher at $1.92 on Friday, and with a total volume of 478,725 shares traded. The Company’s shares have surged 12.28% in the previous three months. The stock is trading below its 50-day moving average by 7.73%. Moreover, shares of Cloud Peak Energy have a Relative Strength Index (RSI) of 42.73.

Harsco Corp. (NYSE: HSC)

Global industrial services and engineered products provider Harsco Corp.’s shares ended last Friday’s session 1.34% higher at $6.03 and with a total volume of 506,657 shares traded. The stock is trading 1.35% below its 50-day moving average. The Company’s shares have an RSI of 41.12.

Uranium Energy Corp. (AMEX: UEC)

Uranium Energy Corp. engages in the exploration, extraction, and processing of uranium concentrates on projects located in the U.S. and Paraguay. The company’s stock closed the session flat at $0.72. A total volume of 1.48 million shares was traded, above their three months average volume of 671,590 shares. The Company’s shares are trading 6.47% below their 50-day moving average. Additionally, shares of Uranium Energy have an RSI of 41.35.

Fairmount Santrol Holdings Inc. (NYSE: FMSA)

On Friday, provider of sand-based proppant solutions, Fairmount Santrol Holdings Inc., closed the session 4.87% higher at $4.52. A total volume of 335,318 shares was traded. The stock has surged 25.21% in the last month, 123.76% over the previous three months, and 92.34% on an YTD basis. The Company’s shares are trading above their 50-day and 200-day moving averages by 42.08% and 51.08%, respectively. Furthermore, Fairmount Santrol Holdings’ stock has an RSI of 67.70. Technical alert on FMSA is available for free at:

http://www.activewallst.com/

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit www.activewallst.com.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom
Email: info@activewallst.com
Phone number: 1-858-257-3144

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: ActiveWallStreet.com

ReleaseID: 440296

• Oneview Solution to Be Deployed In Up To 2,000 Endpoints across the NYU System
• Major Development for the Company Following Recent IPO Success

DUBLIN, IRELAND / ACCESSWIRE / MAY 23, 2016 / Oneview Healthcare (ASX: ONE.AX) the Australian listed Irish Healthcare company today announced the signing of a multi-year contract with NYU Langone Medical Center (“NYU”) to deploy Oneview’s unique software, initially at its 374 bed, Helen L. and Martin S. Kimmel Pavilion, and subsequently across up to a further 2,000 endpoints in the NYU system.

The prestigious contract which comes at an exciting time for the rapidly growing company, following a successful IPO in Australia in March. NYU is one of the top 10 academic medical centers in the U.S. and operates five hospitals, clinics and medical centres throughout New York City’s five boroughs, Long Island, New Jersey, and Westchester, Putnam, and Dutchess counties.

The Oneview platform will allow NYU doctors and nurses to work more efficiently and effectively by providing better, real-time information about the patient. The platform digitizes a range of manual processes, helping staff allocate resources to where they are most needed, helps reduce waste and provides data and analytical tools to measure productivity and identify where further improvements are possible.

Oneview President and Founder Mark McCloskey, who was recently announced as a finalist in the EY Entrepreneur of the Year programme, welcomed the announcement saying: “Oneview is honored to have been selected by one of the United States’ leading academic medical organizations where we believe our leading edge software will provide further innovation. The Oneview platform helps improve productivity, reduce waste and reduce costs for hospitals, and at the same time helps deliver better clinical outcomes for patients while dramatically improving the experience for patients while they are in hospital.”

Mr McCloskey added: “Patients at NYU facilities will benefit from the Oneview software, which includes apps that can be installed on personal tablets and smartphones, to allow patients to learn more about their condition, track their treatment and progress. In addition, patients can exchange messages with doctors and nursing staff, access a wide range of information and entertainment via the internet, live free to air and satellite TV and stay connected to family and friends via live video streaming services such as Skype.”

This announcement demonstrates Oneview’s continued growth and momentum after successfully listing on the Australian Stock Exchange in March 2016. The company which has global aspirations is live and installed in facilities across the US, Australia, Dubai and Ireland. The IPO raised A$62.4 million for Oneview and the company currently has a fully diluted market capitalization of approximately A$235 millions as at 20th May 2016.

ENDS

Enquiries:

Investors:

James Fitter
Chief Executive Officer
Oneview Healthcare
jfitter@oneviewhealthcare.com

Media:

Ireland:
Maria Cryan, Hume Brophy oneview@humebrophy.com

Australia:
Greg Baxter, Newgate Communications Greg.Baxter@newgatecomms.com.au

About NYU Langone Medical Center

NYU Langone Medical Center is one of the nation’s premier academic medical centers. Our trifold mission to serve, teach, and discover is achieved daily through an integrated academic culture devoted to excellence in patient care, education, and research.

Our Leadership, Campus Transformation, and Community Service Plan located in the heart of Manhattan, with additional facilities throughout the New York City area, NYU Langone consists of five hospitals:

• Tisch Hospital, our flagship acute-care facility
• Rusk Rehabilitation, ranked as one of the top 10 rehabilitation programs in the country by U.S. News & World Report since 1989, and recently awarded a three-year accreditation from the Commission on Accreditation of Rehabilitation Facilities (CARF)
• Hospital for Joint Diseases, a dedicated inpatient orthopaedic hospital
• Hassenfeld Children’s Hospital, which provides comprehensive children’s health services across NYU Langone
• The new state-of-the-art, 830,000-square-foot Helen L. and Martin S. Kimmel Pavilion. The Kimmel Pavilion is set to open in 2018 with 374 beds.

NYU Langone is also affiliated with Woodhull Medical Center in Brooklyn, Bellevue Hospital and Gouverneur Health in Manhattan, and the VA NY Harbor Healthcare System. In addition, since April 2015, NYU Lutheran has been an affiliate of NYU Langone, offering Brooklyn residents access to world-renowned care from an academic medical center in their own community.

Specialists at NYU Langone treat a full range of medical conditions in both inpatient and outpatient settings at locations throughout New York City’s five boroughs, Long Island, New Jersey, and Westchester, Putnam, and Dutchess counties.

SOURCE: Oneview Healthcare

ReleaseID: 440303

DALLAS, TX / ACCESSWIRE / May 23, 2016 / EarthWater Inc. www.EarthWater.com a manufacturer of high alkaline mineral infused beverages under the brand FulHum www.FulHum.com announced today the launch of “Delivery to your Door” for FulHum in the Los Angeles, California area with The Water Loft (https://www.thewaterloft.com/fulhum_water_delivery.php?categories_id=64).

The Water Loft’s goals are to bring LA’s urban dwellers and businesses premium select waters (artesian, spring, structured, oxygenated and functional beverages) delivered to your door. The Water Loft acknowledges the lifestyle their customers have chosen and provides them with the service that will suit their daily needs. Consumers will no longer have to carry heavy cases of water from the market to their home or office.

The Water Loft owners, Debbie and Howard Nodelman, stated, “Water is essential for life and we invite you to browse and shop online and thank everyone for making us a part of your neighborhood.” For more info visit www.thewaterloft.com.

EarthWater Chairman, CJ Comu stated, “This is a great addition to our distribution network to bring FulHum to residential, office and commercial customers in California.”

About EarthWater and FulHum

FulHum www.FulHum.com www.FulHum.co.uk www.FulHum.cn is a product of EarthWater Limited www.EarthWater.com FulHum is a Mineral-Infused High Alkaline Beverage which is a 100% natural, proprietary blend of natural Fulvic and Humic complexes mined from deep within the earth’s surface. For more info on EarthWater email; info@earthwater.com

SOURCE: EarthWater Inc.

ReleaseID: 440302

BEDMINSTER, NJ / ACCESSWIRE / May 23, 2016 / CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today Dr. Christoph Wanner, Professor of Medicine and Director of Nephrology at the University of Wurzburg, delivered an oral presentation titled, “A Novel Taurolidine Containing Catheter Lock Solution (CLS) Without Reported Antimicrobial Resistance, Reduces the Rates of Infection and Thrombosis in Hemodialysis Patients Enrolled in a Post-Approval Surveillance Study” at the 53rd ERA-EDTA Congress in Vienna, Austria.

In the study, Dr. Wanner evaluated the use of Neutrolin, CorMedix’s CE Marked anti-infective solution for the prevention of catheter-related blood infections (CRBSIs) and thrombosis, which are the major complications observed in patients undergoing hemodialysis with indwelling central venous catheters. Under the study, 202 hemodialysis patients at 20 hemodialysis centers in Germany were enrolled in the ongoing Neutrolin Use Monitoring Program (NUMP), representing 15,464 dialysis sessions over a 26-month period, for a total of 36,083 hemodialysis catheter days. These data demonstrated that use of Neutrolin is associated with 96.0% reduction in the rate of CRBSI and 96.7% reduction in thrombosis compared to published historical benchmarks of 3.5 CRBSIs and 2-3 episodes of thrombosis per 1,000 catheter days. No significant adverse drug reactions that led to the discontinuation of Neutrolin use were reported.

Randy Milby, CorMedix CEO, said, “The medical community around the world have shown interest in Neutrolin’s real world clinical performance in preventing catheter-related infections and thrombosis, as bloodstream infections remain a primary concern for hospitals worldwide. This presentation demonstrates our strong interest in gaining clinical acceptance of Neutrolin around the world by developing and sharing clinical data supporting Neutrolin’s use in patients with indwelling venous catheters required for vascular access in various settings including hemodialysis, oncology, critical care, parenteral nutrition, IV hydration and/or IV medications.”

Christoph Wanner, M.D., Lead Author and Professor of Medicine, Head of Nephrology, Department of Medicine, Division of Nephrology and Scientific director, Clinical Trial Unit, at University Hospital of Würzburg, stated, “Catheter Related Bloodstream Infections and thrombosis are the major healthcare complications in HD patients, creating a need for effective treatments. The results of our study support the use of Neutrolin in reducing CVC related complications of infection and thrombosis in HD patients.”

About CorMedix Inc.

CorMedix Inc. is an emerging commercial-stage biopharmaceutical company that initiated a Phase 3 clinical study of a novel anti-infective solution Neutrolin in hemodialysis patients in the United States in December 2015. The Company seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of infectious and inflammatory diseases. CorMedix’s first commercial product in Europe is Neutrolin®, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients, in addition to oncology patients, critical care patients, and patients receiving total parenteral nutrition, IV hydration, and/or IV medications. The FDA has granted Fast Track status to Neutrolin Catheter Lock Solution and also has designated Neutrolin as a Qualified Infectious Disease Product for oncology, hemodialysis, and critical care/intensive care patients, where catheter-related blood stream infections and clotting can be life-threatening. The initial and planned indications aim to address significant needs in catheter-based treatments in the U.S. and the rest of the world. For more information visit: www.cormedix.com.

For Investors & Media:

Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D.
jdrumm@tiberend.com
(212) 375-2664

Janine McCargo
jmccargo@tiberend.com
(646) 604-5150

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects, future financial position, financing plans, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including: the results of studies regarding Neutrolin® conducted by us and others; the cost, timing and results of the planned Phase 3 trials for Neutrolin® in the U.S.; obtaining regulatory approvals to conduct clinical trials and to commercialize CorMedix’s product candidates, including marketing of Neutrolin in countries other than Europe; obtaining additional financing to support CorMedix’s research and development and clinical activities and operations; the risks associated with the launch of Neutrolin in new markets; CorMedix’s ability to enter into, execute upon and maintain collaborations with third parties for its development and marketing programs; CorMedix’s ability to maintain its listing on the NYSE MKT; the risks and uncertainties associated with CorMedix’s ability to manage its limited cash resources; the outcome of clinical trials of CorMedix’s product candidates and whether they demonstrate these candidates’ safety and effectiveness; CorMedix’s ability to identify and enter into strategic transactions; CorMedix’s dependence on its collaborations and its license relationships; achieving milestones under CorMedix’s collaborations; CorMedix’s dependence on preclinical and clinical investigators, preclinical and clinical research organizations, manufacturers, sales and marketing organizations, and consultants; and protecting the intellectual property developed by or licensed to CorMedix. These and other risks are described in greater detail in CorMedix’s filings with the SEC, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

SOURCE: CorMedix Inc.

ReleaseID: 440277

LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include Intuit, NQ Mobile, Imperva, and Qualys.

Today, ActiveWallSt.com is promoting its technical alert briefings. Get all of our alerts free by signing up to http://www.activewallst.com/.

The Technology sector continues to impress the investors’ community at large, and everyone on the street is watching how some of the top names in this sector are faring. Access today’s complimentary technical alert services on these equities at:

http://www.activewallst.com/

Below is a brief market recap of the above-mentioned stocks’ performances at the closing bell last Friday:

Intuit Inc. (NASDAQ: INTU)

Business and financial management solutions provider Intuit Inc.’s stock finished the trading session 1.59% higher at $103.03 with a total volume of 1.16 million shares traded. The Company’s shares have gained 0.71% in the last one month, 5.17% over the previous three months, and 7.41% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 0.86% and 6.95%, respectively. Furthermore, shares of Intuit have a Relative Strength Index (RSI) of 53.90.

NQ Mobile Inc. (NYSE: NQ)

Last Friday, shares in mobile Internet services provider, NQ Mobile Inc., recorded a trading volume of 2.84 million shares, above their three months average volume of 1.09 million shares. The stock ended the session at 2.65% higher at $3.88. The Company’s shares have advanced 4.86% over the previous three months and 6.59% on an YTD basis. The stock is trading 0.60% above its 200-day moving average. Moreover, shares of NQ Mobile have an RSI of 35.36.

Imperva Inc. (NYSE: IMPV)

Cyber security solutions developer and provider Imperva Inc.’s stock ended the day 2.56% higher at $35.20. A total volume of 554,831 shares was traded, above their three months average volume of 514,940 shares. The Company’s shares are trading 21.76% below their 50-day moving average. Additionally, shares of Imperva have an RSI of 33.64.

Qualys Inc. (NASDAQ: QLYS)

Shares in Qualys Inc., provider of cloud-based security and compliance solutions, recorded a trading volume of 645,451 shares, above their three months average volume of 507,180 shares. The stock ended Friday’s session 4.60% higher at $29.11. The Company’s shares have surged 16.72% in the last month and 24.72% over the previous three months. The stock is trading above its 50-day moving average by 13.84%. Furthermore, shares of Qualys have an RSI of 76.72. The complete technical setup on QLYS is available for free at:

http://www.activewallst.com/

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit www.activewallst.com.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom
Email: info@activewallst.com
Phone number: 1-858-257-3144

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: ActiveWallStreet.com

ReleaseID: 440291

LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include Novo Nordisk, Biodel, Sucampo Pharma, and SciClone Pharma.

Today, ActiveWallSt.com is promoting its technical alert briefings. Get all of our alerts free by signing up to http://www.activewallst.com/.

Despite pressures in pricing and competition, the Drug Manufacturers industry continues to present opportunities to many investors. Let us see how investors see some of the big names within this space. Find out how you can benefit from these stocks’ technical alerts at:

http://www.activewallst.com/

Let us see how these equities performed at their last close on Friday, May 20, 2016:

Novo Nordisk A/S (NYSE: NVO)

Shares in healthcare company, Novo Nordisk A/S, gained 0.41%, finishing the trading session at $53.92 with a total volume of 1.01 million shares traded. The stock has advanced 6.35% over the previous three months. The Company’s shares are trading below their 200-day moving averages by 0.54%. Additionally, Novo Nordisk’s stock has a Relative Strength Index (RSI) of 44.11.

Biodel Inc. (NASDAQ: BIOD)

Shares of specialty biopharmaceutical company, Biodel Inc., ended the session at $0.39, gaining 1.59%. The stock recorded a trading volume of 1.05 million shares. The Company’s shares have advanced 18.18% in the previous three months and 14.71% on an YTD basis. The stock is trading 4.31% above its 50-day moving average. Moreover, shares of Biodel have an RSI of 53.05.

Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP)

On Friday, shares in Sucampo Pharmaceuticals Inc. recorded a trading volume of 305,273 shares. The stock edged 4.04% higher, closing the day at $11.59. The Company’s shares are trading 5.82% above their 50-day moving average. Additionally, Sucampo Pharmaceuticals’ stock has an RSI of 60.80.

SciClone Pharmaceuticals Inc. (NASDAQ: SCLN)

SciClone Pharmaceuticals Inc. is a specialty pharmaceutical company that offers therapies for oncology, infectious diseases, and cardiovascular disorders in China, the U.S., and Hong Kong. Shares of the Company recorded a trading volume of 348,034 shares on Friday. The stock ended the session at $12.54, gaining 0.48%. The Company’s shares have advanced 36.75% in the previous three months and 36.30% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 6.41% and 36.49%, respectively. Furthermore, shares of SciClone Pharma have an RSI of 53.95. Technical alert on SCLN is available for free at:

http://www.activewallst.com/

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit www.activewallst.com.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom
Email: info@activewallst.com
Phone number: 1-858-257-3144

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: ActiveWallStreet.com

ReleaseID: 440294

LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include Abercrombie & Fitch, Francesca’s Holdings, Tailored Brands, and Children’s Place.

Today, ActiveWallSt.com is promoting its technical alert briefings. Get all of our alerts free by signing up to http://www.activewallst.com/

Below is our brief technical snapshot on today’s featured companies on the apparel stores industry. Let us scan their performances over the last few sessions. Register now to have free access to the technical alerts on these stocks at:

http://www.activewallst.com/

Abercrombie & Fitch Co. (NYSE: ANF)

Last Friday, specialty retailer of casual apparel Abercrombie & Fitch Co.’s stock climbed 2.26% to close the day at $24.42. A total volume of 3.09 million shares was traded, above their three months average volume of 2.39 million shares. The Company’s shares are trading 0.57% below their 200-day moving average. Additionally, shares of Abercrombie & Fitch have a Relative Strength Index (RSI) of 38.29.

Francesca’s Holdings Corp. (NASDAQ: FRAN)

Shares in Francesca’s Holdings Corp., the operator of a chain of retail women’s apparel and accessories boutiques, climbed 1.44%, finishing Friday’s session at $10.56. The stock recorded a trading volume of 1.55 million shares, above its three months average volume of 1.24 million shares. The Company’s shares are trading below their 200-day moving average by 31.38%. Furthermore, Francesca’s Holdings’ stock traded at a PE ratio of 11.62 and has an RSI of 15.40.

Tailored Brands Inc. (NYSE: TLRD)

Specialty apparel retailer Tailored Brands Inc.’s stock finished 2.66% higher at $12.72 last Friday at the close. A total volume of 1.34 million shares was traded, above their three months average volume of 991,210 shares. The Company’s shares are trading below their 50-day moving average by 23.30%. Additionally, shares of Tailored Brands have an RSI of 28.56.

The Children’s Place Inc. (NASDAQ: PLCE)

Shares in kids’ specialty apparel retailer, The Children’s Place Inc., ended last Friday’s session 1.62% higher at $74.61 and with a total volume of 663,209 shares traded. The stock has advanced 14.71% over the previous three months and 35.50% on an YTD basis. The Company’s shares are trading 18.67% above their 200-day moving average. Moreover, The Children’s Place’s stock has an RSI of 50.67. PLCE free technical alert is just a click away at:

http://www.activewallst.com/

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit www.activewallst.com

CONTACT

For any questions, inquiries, or comments reach out to us directly at: 

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom
Email: info@activewallst.com
Phone number:  1-858-257-3144

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: 

ReleaseID: 440290